Company Monitoring Page for Alnylam

latest headlines for company on cafepharma

Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran)
Pharmaceutical Business Review
Thu, 03/26/20 - 10:22 am
Tags:
Alnylam, RNAi, Gen, Onpattro, Turkey, hATTR amyloidosis
Alnylam, Vir team up to develop siRNAs to tackle COVID-19
Fierce Biotech
Wed, 03/4/20 - 10:52 am
Tags:
Alnylam, Vir Biotechnology, RNAi, coronaviruses, COVID-19, siRNA
Ex-Sanofi chief Olivier Brandicourt, current Blackstone advisor, jumps on Alnylam board
Endpoints
Fri, 02/28/20 - 10:44 am
Tags:
Sanofi, Olivier Brandicourt, Alnylam
With Rising Drug Prices a Concern, Some Companies Enact Their Own Control Plans
BioSpace
Wed, 01/15/20 - 10:59 am
Tags:
drug pricing, Roche, Eli Lilly, Amgen, Alnylam, Sanofi
JPM: Alnylam CEO looks to action-packed 2020 on the heels of Givlaari approval
Fierce Pharma
Tue, 01/14/20 - 10:44 am
Tags:
Alnylam, RNAi, Givlaari, John Maraganore, JPMHC 2020
3 Rare Disease Drug Launches to Watch in 2020
Motley Fool
Sat, 01/4/20 - 07:38 pm
Tags:
Global Blood Therapeutics, sickle cell disease, Oxbryta, Novartis, SCD, Adakveo, Alnylam, Givlaari, acute hepatic porphyria, FDA
With trial win, Alnylam to seek approval for first treatment of rare kidney disease
Biopharma Dive
Tue, 12/17/19 - 10:29 am
Tags:
Alnylam, lumasiran, clincial trials, RNAi, kidney disease, Primary Hyperoxaluria
5 New Drug Approvals the FDA Gave Top Priority
Motley Fool
Sat, 11/30/19 - 11:22 pm
Tags:
FDA, drug approvals, Global Blood Therapeutics, Oxbryta, Alnylam, Givlaari, BeiGene, Brukinsa, Vertex Pharmaceuticals
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
RAPS.org
Wed, 11/27/19 - 12:39 pm
Tags:
FDA, Vertex Pharmaceuticals, Trikafta, Novartis, Adakveo, Alnylam, Givlaari, BeiGene, Brukinsa, Global Blood Therapeutics, Oxbryta, drug approvals
Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class
Motley Fool
Sat, 11/23/19 - 04:05 pm
Tags:
RNAi, Givlaari, Alnylam
FDA's rapid review pace nets an early approval for Alnylam's second drug
Biopharma Dive
Wed, 11/20/19 - 10:51 pm
Tags:
FDA, Alnylam, Givlaari, givosiran, RNAi, porphyria
The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down
Yahoo/Benzinga
Sun, 11/17/19 - 08:47 pm
Tags:
AHA, The Medicines Company, Intrexon, Alnylam, Pieris, Roche
These Biotechs Were Focused on One Line on Pfizer’s Earnings Report
Motley Fool
Thu, 10/31/19 - 11:51 pm
Tags:
Pfizer, Vyndaqel, Alnylam, Akcea Therapeutics, Ionis Pharmaceuticals, Eidos Therapeutics
Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test
EP Vantage
Sat, 10/19/19 - 01:36 pm
Tags:
Novartis, fevipiprant, severe asthma, Alnylam, lumasiran, Primary Hyperoxaluria
Pfizer's Vyndaqel franchise, buoyed by diagnoses, is poised for 'a decisive beat': analyst
Fierce Pharma
Fri, 10/18/19 - 07:45 pm
Tags:
Pfizer, tafamidis, FDA, Vyndaqel, Alnylam, Ionis, ATTR amyloidosis
Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn
Fierce Pharma
Tue, 07/9/19 - 06:32 pm
Tags:
Ionis, Tegsedi, RNAi, Alnylam, Onpattro, NICE
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
Xconomy
Mon, 05/20/19 - 09:41 am
Tags:
The Medicines Company, Alnylam, inclisiran
Can Pfizer Leap Over the Competition With This Potential Blockbuster?
Motley Fool
Wed, 05/8/19 - 10:03 am
Tags:
Pfizer, Vyndamax, tafamidis, ATTR, Alnylam, Onpattro, Akcea Therapeutics, Tegsedi, Eidos Therapeutics, AG10
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
Xconomy
Mon, 05/6/19 - 10:54 am
Tags:
FDA, Pfizer, tafamidis, Vyndaqel, Vyndamax, ATTR, Alnylam, Akcea
Vendu! Weeks after Sanofi cuts ties to Alnylam, the pharma giant offloads $842M of its stock
Endpoints
Fri, 05/3/19 - 10:52 pm
Tags:
Sanofi, Alnylam

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.